TickerTalks
Browse all tickers →
TickerTalks›$RGC
RGRGC

Regencell Bioscience Holdings Limited

$RGC·$2.7B·Drug Manufacturers - Specialty & Generic·Healthcare
$5.24+3.6%YTD-72.5%1Y-61.0%
Mentions · last 7 days
2026-08-06: 7 posts2026-08-07: 8 posts2026-08-08: 2 posts2026-08-09: 5 posts2026-08-10: 11 posts2026-08-11: 10 posts2026-08-12: 5 posts50+13%
Price updated 7h ago·X counts updated 1d ago
RGRGC
$RGCRegencell Bioscience Holdings Limited
$5.24+3.56%50 posts+13%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $RGC, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeSelling offAI verdict · as of 2026-08-12

Falling on heavy selling — points lower unless it turns around.

Squeeze-tale name down 73% YTD to $5 despite zero borrow available — the story keeps unwinding.

Regencell Bioscience is a former squeeze-tale name whose fundamentals never showed up — the tape has spoken.

What the numbers say:

  • Price $5.02, -73% YTD and -63% over twelve months — a genuine downtrend, not a base.
  • Fundamentals: PE -603 (essentially no earnings), zero revenue reported (PS 0), ROIC -444%, D/E 0.32. This is a pre-revenue TCM name, not an operating business.
  • Bull thesis remains a mechanical squeeze setup: zero shares available to borrow, 255% borrow fee, CEO owning ~90% of shares locked up, recent offering closing above $20, and $10 flagged as parabolic trigger.
  • Bear read is the reality: the stock is at $5.25 after $70+ callouts; shorts who took the risk are up more than 1300%.

The squeeze mechanics exist; the fundamentals don't — this is a mechanic vs. gravity setup and gravity has been winning.

Differs from X sentimentX is split — bulls on the squeeze mechanics, bears on the price action. Our read leans with the bears: absent any operational catalyst, the squeeze thesis hasn't paid off.

What to watch: Any material product/clinical news, changes in the borrow-availability mechanics, and the Oct 28 date on the calendar for any corporate update.

On the calendar: 2026-10-28 — corporate update

off topic mix

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment6 posts analyzed · as of 2026-07-14

$RGC chatter is split between bulls building a squeeze thesis—zero shares available to borrow, 255% short-borrow fee, CEO owning nearly 90% of shares locked up, recent offering closing above $20, and $10 flagged as the parabolic trigger—and a bear victory lap noting the stock is now trading at $5.25 after $70+ callouts, with commentators who shorted still up more than 1300%.

Read the AI verdict + X sentiment for $RGC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biotech developing Traditional Chinese Medicine therapies targeting ADHD and neurocognitive disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $RGC.

Drug Manufacturers - Specialty & Generic · Healthcare

No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..

What this means for $RGC

Neutral — Biotech developing Traditional Chinese Medicine therapies targeting ADHD and neurocognitive disorders; limited read-through from drug manufacturers - specialty & generic macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+50.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-602.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-444%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-232%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 15, 2026$-0.01——
Q3 2025Nov 18, 2025$-0.00——
Q1 2025Jun 26, 2025$-0.14——
Q3 2024Oct 25, 2024$-0.00——
Next earningsWed, Oct 28

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.01—
Q4 FY25$0———$-0.00$0
Q2 FY25$0———$-0.00$0
Q4 FY24$0-100.0%——$-0.00$-2.0M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.1%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-43.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-74.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 17.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.495-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 2 other (2 returns) in window

See when $RGC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)May 19424B5
AI summary

Regencell Bioscience Holdings (RGC) filed a 424B5 prospectus supplement on May 19, 2026 for a registered direct offering of 985,222 ordinary shares at $20.30/share — a ~27% discount to the prior close of $27.79 — raising $20.0M gross ($18.7M net after $1.3M placement agent fees). Univest Securities acted as placement agent and also purchased 49,262 shares as principal for $1M of its own account. Immediate dilutive offering at a steep discount — material capital structure event for this small-cap biotech.

424B5Prospectus supplement (offering)Mar 30424B5
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 9 other (7 6-Ks · 1 F-3ASR · 1 3) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

RGC Resources Q3 Earnings Call Highlightsmarketbeat.com·7d agoRGC Resources, Inc. Reports Third Quarter Earningsglobenewswire.com·9d agoUnited Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promisesseekingalpha.com·39d agoRGC Resources, Inc. Declares Quarterly Dividendglobenewswire.com·46d agoPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGCglobenewswire.com·52d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ACB$ZYBT$CRON$EMBC$ELAN$TAK$BHC$LNTH
Voices on X · last 7 days

No standout posts about $RGC on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport